
Genor Biopharma Announces EGM for Merger and Retention Plan Approval

I'm PortAI, I can summarize articles.
Genor Biopharma Holdings Limited has announced an Extraordinary General Meeting on December 22, 2025, to discuss and potentially approve a proposed merger and a retention plan. The merger involves issuing shares to target shareholders, and the retention plan requires approval under the Takeovers Code. These resolutions could significantly impact the company’s strategic direction and shareholder value.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

